- Home
- GRI vs BLUWW Comparison
GRI vs BLUWW Comparison
Compare GRI & BLUWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GRI | BLUWW |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9M | 1.8M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | GRI | BLUWW |
|---|---|---|
| Price | $0.34 | $0.58 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | N/A |
| Earning Date | 11-14-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | N/A |
| 52 Week High | $15.64 | N/A |
Technical Indicators
Market Signals| Indicator | GRI | BLUWW |
|---|---|---|
| Relative Strength Index (RSI) | 20.64 | N/A |
| Support Level | $0.33 | N/A |
| Resistance Level | $2.17 | N/A |
| Average True Range (ATR) | 0.13 | 0.00 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 1.86 | 0.00 |
Price Performance
Historical ComparisonAbout GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.